BRITISH JOURNAL OF HAEMATOLOGY

Volume 119, Issue 1, October 2002

IMAGES IN HAEMATOLOGY

1 **Superior vena cava syndrome and hypercalcaemia in a patient with a primary mediastinal B-cell lymphoma secreting parathyroid hormone-related protein**
L.-T. Hsiao, T.-J. Chiou, I.-T. Yu and P.-M. Chen

2 **Intravascular lymphomatosis of the prostate gland**
C. S. Chim and F. Loong

REVIEWS

3 **Combination therapy with imatinib mesylate (STI571): synopsis of *in vitro* studies**
J. Topaly, W. J. Zeller and S. Fruehauf

15 **STI-571 in chronic myelogenous leukaemia**
A. S. Tsao, H. Kantarjian and M. Talpaz

ANNOTATION

25 **Haematological care of the Jehovah's Witness patient**
J. C. W. Marsh and D. H. Bevan

HAEMATOLOGICAL MALIGNANCY

38 **Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival**
F. J. Giles, H. M. Kantarjian, B. N. Bekele, J. E. Cortes, S. Faderl, D. A. Thomas, T. Manshouri, A. Rogers, M. J. Keating, M. Talpaz, S. O'Brien and M. Albitar

46 **Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia**
D. Tzoanopoulos, M. Speletas, K. Arvanitidis, C. Veiopoulou, S. Kyriaki, G. Thyphronitis, P. Sideras, G. Kartalis and K. Ritis

54 **Myeloma clonotypic B cells are hampered in their ability to undergo B-cell differentiation *in vitro***
J. E. J. Guikema, E. Vellenga, M. H. C. Bakkus and N. A. Bos

62 **Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits ('aggregoma'): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses**
A. Rostagno, G. Frizzera, L. Ylagan, A. Kumar, J. Ghiso and G. Gallo

70 **CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression**
R. Luque, J. A. García-Trujillo, C. Cámara, A. Moreno, P. Eiras, G. Roy, L. M. Villar, M. Lombardía, J. A. Brieva, A. Bootello and E. Roldán

79 **Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies**
M. Hedenus, S. Hansen, K. Taylor, C. Arthur, B. Emmerich, C. Dewey, D. Watson, G. Rossi and A. Österborg on behalf of the Darbepoetin alfa 990114 Study Group

87 **Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number**
G. B. Tennant, A. I. Al-Sabah and A. K. Burnett

97 **Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome**
J. J. Melenhorst, R. Eniafe, D. Follmann, R. Nakamura, M. Kirby and A. J. Barrett

Short reports

106 **Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid**
N. Takayama, N. Sato, S. G. O'Brien, Y. Ikeda and S.-i. Okamoto

109 **Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571**
C. Barthe, M.-j. Gharbi, V. Lagarde, C. Chollet, P. Cony-Makhoul, J. Reiffers, J. M. Goldman, J. V. Melo and F. X. Mahon

112 **Identification and characterization of a novel gene encoding a *SEREX* antigen in chronic myeloid leukaemia**
S. A. Rogers, D. J. Bowen, M. Ling, P. Thomson, Z. Wang and S. H. Lim

115 **Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of $CD34^+/CD38^-$ primitive haematopoietic progenitors**
M. Mohty, D. Isnardon, N. Vey, F. Brière, D. Blaise, D. Olive and B. Gaugler

119 **Frequent co-expression of *HoxA9* and *Meis1* genes in infant acute lymphoblastic leukaemia with *MLL* rearrangement**
T. Imamura, A. Morimoto, M. Takanashi, S. Hibi, T. Sugimoto, E. Ishii and S. Imashuku

122 **Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma**
D. Molin, A. Edström, I. Glimelius, B. Glimelius, G. Nilsson, C. Sundström and G. Enblad

125 **Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma**
K. W. Song, P. Mollee, B. Patterson, W. Brien and M. Crump

128 **Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report**
E. A. Wilson, S. Jobanputra, R. Jackson, A. N. Parker and I. G. McQuaker

131 **Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome**
N. T. Ueno, A. Anagnostopoulos, G. Rondón, R. E. Champlin, N. Mikhailova, O. S. Pankratova, L. S. Zoubarovskaya, E. V. Semenova, B. V. Afanasyev, S. O'Brien, M. Andreeff and A. Y. Zaritskey

TRANSPLANTATION

135 **Influence of the different CD34$^+$ and CD34$^-$ cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors**
P. Menéndez, J. A. Pérez-Simón, M. V. Mateos, M. D. Caballero, M. González, J. F. San-Miguel and A. Orfao

144 **Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens**
J. E. Parker, T. Shafi, A. Pagliuca, A. Mijovic, S. Devereux, M. Potter, H. G. Prentice, M. Garg, J. A. Yin, J. Byrne, N. H. Russell and G. J. Mufti

155 **H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation**
J.-F. Lambert, G. A. Colvin, S. Zhong, H. Wang, L. D'Hondt, M. Abedi, A. E. Frimberger, F. M. Stewart and P. J. Quesenberry

Short report 164 **Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients**
A. B.-T. Fassas, T. Spencer, R. Desikan, M. Zangari, E. Anaissie, B. Barlogie and G. Tricot

PLATELETS, HAEMOSTASIS AND THROMBOSIS

169 **Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis**
A. van Hylckama Vlieg, N. Komanasin, R. A. S. Ariëns, S. R. Poort, P. J. Grant, R. M. Bertina and F. R. Rosendaal

Short report 176 **Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y**
W. A. Lester, M. D. Williams, S. L. Allford, M. S. Enayat and S. J. Machin

HAEMOPOIESIS AND LEUCOCYTES

180 **Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression**
M. Aricò, M. Allen, S. Brusa, R. Clementi, D. Pende, R. Maccario, L. Moretta and C. Danesino

189 **Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells**
U. Grigoleit, S. Riegler, H. Einsele, K. L. Sampaio, G. Jahn, H. Hebart, P. Brossart, F. Frank and C. Sinzger

199 **Human monocytes synthesize hyaluronidase**
N. Girard, C. Maingonnat, P. Bertrand, H. Tilly, J.-P. Vannier and B. Delpech

204 **Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy**
F. J. Radcliff, D. A. Caruso, C. Koina, M. J. Riordan, A. W. Roberts, M. L. K. Tang, C. M. Baum, S. L. Woulfe and D. M. Ashley

212 **Laminin γ2 chain as a stromal cell marker of the human bone marrow microenvironment**
U. Siler, P. Rousselle, C. A. Müller and G. Klein

221 **Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions**
N. P. Connolly, M. Jones and S. M. Watt

Short report 239 **Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids**
D. J. Schaer, F. S. Boretti, G. Schoedon and A. Schaffner

RED CELLS

244 **Influence of different radioprotective compounds on radiotolerance and cell cycle distribution of human progenitor cells of granulocytopoiesis *in vitro***
W. Klingler, L. Kreja, W. Nothdurft and C. Selig

255 **Fetal *RHD* genotyping in maternal serum during the first trimester of pregnancy**
J.-M. Costa, Y. Giovangrandi, P. Ernault, L. Lohmann, V. Nataf, N. El Halali and E. Gautier

Short reports 261 **Familial transient erythroblastopenia of childhood is associated with the chromosome 19q13.2 region but not caused by mutations in coding sequences of the ribosomal protein S19 (RPS19) gene**
P. Gustavsson, J. Klar, H. Matsson, E. Forestier, J.-I. Henter, S. Rao, M. Seip, G. Skeppner and N. Dahl

265 **Unusual phenotypic observations associated with a rare HbH disease genotype ($--^{Med}/\alpha^{TSaudi}\alpha$): implications for clinical management**
J. Traeger-Synodinos, I. Papassotiriou, M. Karagiorga, E. Premetis, E. Kanavakis and A. Stamoulakatou

CORRESPONDENCE

268 **Position paper on imatinib mesylate in chronic myeloid leukaemia**
S. G. O'Brien and S. A. J. Rule

272 **BCR-ABL FISH monitoring of CML: a survey of current UK practice**
M. W. Drummond, L. M. Hendry, E. Maher and T. L. Holyoake

274 **STI571-induced Stevens–Johnson syndrome**
D. Vidal, L. Puig, A. Sureda and A. Alomar

275 **Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF**
V. Pitini, D. Teti, C. Arrigo, G. Aloi and M. Righi

276 **Serum levels of VEGF do not correlate with the severity of multiple myeloma**
C. Jakob, I. Zavrski, U. Heider, C. Langelotz, J. Eucker, K. Possinger and O. Sezer

276 **Reply to Sezer *et al***
T. Iwasaki

277 **$P15^{INK4B}$ is not mutated in adult familial myelodysplastic syndromes**
E. Cameron, A. Mijovic, J. G. Herman, S. B. Baylin, A. Pradhan, G. J. Mufti and F. V. Rassool

279 **Red cell aplasia due to parvovirus B19 in a patient treated with alemtuzumab**
B. Crowley and B. Woodcock

280 **Parvovirus B19-associated pure red cell aplasia in chronic graft-versus-host disease**
J. W. Hsu, M. Czader, V. Anders, G. Vogelsang and R. A. Brodsky

282 **Congenital afibrinogenaemia in a newborn infant due to a novel mutation in the fibrinogen Aα gene**
J. J. Vlietman, J. Verhage, H. L. Vos, R. van Wijk, J. A. Remijn, W. W. van Solinge and F. Brus
283 **Relapse of severe aplastic anaemia after influenza immunization**
C. L. Hendry, M. Sivakumaran, J. C. W. Marsh and E. C. Gordon-Smith
284 **Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. Control of bleeding by recombinant factor VIIa**
R. Lecumberri, C. Panizo, J. A. Páramo, M. P. Salazar and E. Rocha
286 **The use of recombinant factor VIIa in a Jehovah's Witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage**
D. P. Waddington, F. T. McAuley, J. P. Hanley and G. P. Summerfield
289 **ERRATA**
290 **ANNOUNCEMENT**

Volume 119, Issue 2, November 2002

291 **EDITORIAL**

IMAGES IN HAEMATOLOGY

293 **Pyothorax-associated lymphoma**
M. Yasukawa, M. Hamada and K. Ohshima
294 **Thrombus in harvested marrow from a patient with recent heparin-induced thrombocytopenia**
M. J. Bowers and F. G. C. Jones

GUIDELINE

295 **The investigation and management of neonatal haemostasis and thrombosis**
M. D. Williams, E. A. Chalmers and B. E. S. Gibson

REVIEWS

310 **Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?**
P. C. Spiegel Jr and B. L. Stoddard
323 **Factor VIII – novel insights into form and function**
E. L. Saenko, N. M. Ananyeva, E. G. D. Tuddenham and G. Kemball-Cook

PLATELETS, HAEMOSTASIS AND THROMBOSIS

332 **The uptake of recombinant factor VIII in the Netherlands**
J. E. F. Zwart-van Rijkom, I. Plug, F. R. Rosendaal, H. G. M. Leufkens and A. W. Broekmans on behalf of the Study Group of Haemophilia in the Netherlands

342 **Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors**
J. Astermark, M. Ekman and E. Berntorp

348 **Human platelet alloantigen polymorphism in Glanzmann's thrombasthenia and its impact on the severity of the disease**
K. Ghosh, B. Kulkarni, S. Nair, S. Shetty and D. Mohanty

354 **Platelet autoantibodies and lupus-associated thrombocytopenia**
M. Michel, K. Lee, J.-C. Piette, P. Fromont, A. Schaeffer, P. Bierling and B. Godeau

359 **Expression of stanniocalcin-1 in megakaryocytes and platelets**
M. Serlachius, R. Alitalo, H. S. Olsen and L. C. Andersson

364 **Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods**
I. Jennings, M. Greaves, I. J. Mackie, S. Kitchen, T. A. L. Woods and F. E. Preston on behalf of the UK National External Quality Assessment Scheme for Blood Coagulation

370 **Reliability of point-of-care prothrombin time testing in a community clinic: a randomized crossover comparison with hospital laboratory testing**
C. R. Shiach, B. Campbell, L. Poller, M. Keown and N. Chauhan

376 **A family of textilinin genes, two of which encode proteins with antihaemorrhagic properties**
I. Filippovich, N. Sorokina, P. P. Masci, J. de Jersey, A. N. Whitaker, D. J. Winzor, P. J. Gaffney and M. F. Lavin

385 **C-reactive protein in the diagnosis of deep vein thrombosis**
R. A. Bucek, M. Reiter, P. Quehenberger and E. Minar

Short reports

390 **Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A**
C. Mazurier, A. Parquet-Gernez, C. Gaucher, J.-M. Lavergne and J. Goudemand

393 **Analysis of factor VIII inhibitors in a haemophilia A patient with an $Arg^{593} \rightarrow Cys$ mutation using phage display**
W. S. Bril, E. A. M. Turenhout, P. H. P. Kaijen, E. N. van den Brink, M. M. W. Koopman, M. Peters and J. Voorberg

397 **Severe methylenetetrahydrofolate reductase deficiency revealed by a pulmonary embolism in a young adult**
C. Tonetti, M. Ruivard, V. Rieu, J. Zittoun and S. Giraudier

HAEMATOLOGICAL MALIGNANCY

400 **Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis**
W. H. Park, J. G. Seol, E. S. Kim, W. K. Kang, Y. H. Im, C. W. Jung, B. K. Kim and Y. Y. Lee

408 **The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre**
S. J. Howell, M. Grey, J. Chang, G. R. Morgenstern, R. A. Cowan, D. P. Deakin and J. A. Radford

412 **Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review**
G. A. Kennedy, S.-K. Tey, R. Cobcroft, P. Marlton, G. Cull, K. Grimmett, D. Thomson and D. Gill

417 **Major histocompatibility complex abnormalities in non-Hodgkin lymphomas**
B. Drénou, G. Le Friec, M. Bernard, C. Pangault, J.-M. Grosset, T. Lamy, R. Fauchet and L. Amiot

425 **Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas**
L. Chaperot, O. Manches, J. Q. Mi, A. Moine, M.-C. Jacob, R. Gressin, J.-P. Molens, J.-J. Sotto, D. Leroux, J.-C. Bensa and J. Plumas

432 **Hodgkin's disease in the elderly: a population-based study**
G. L. Stark, K. M. Wood, F. Jack, B. Angus, S. J. Proctor and P. R. Taylor on behalf of the Northern Region Lymphoma Group

441 **Isolated parenchymal lung involvement in children with stage IV Hodgkin's disease: results of the UKCCSG HD8201 and HD9201 studies**
A. Atra, E. Higgs, M. Capra, A. Elsworth, J. Imeson, M. Radford, R. Pinkerton and M. Hewitt on behalf of the United Kingdom Children Cancer Study Group (UKCCSG)/Hodgkin's Disease Group

445 **Prospective molecular monitoring of BCR/ABL transcript in children with Ph^+ acute lymphoblastic leukaemia unravels differences in treatment response**
G. Cazzaniga, M. Lanciotti, V. Rossi, D. Di Martino, M. Aricò, M. G. Valsecchi, G. Basso, G. Masera, C. Micalizzi and A. Biondi

454 **Identification of an ETV6–ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line**
F. Griesinger, A. Janke, M. Podleschny and S. K. Bohlander

459 **Autologous lymphocytes as vectors to target therapeutic radiation, using indium-114m, in patients with lymphoid cell malignancy**
R. A. Cowan, B. Murby, D. Gunton, S. E. Owens, K. P. Hoyes, H. L. Sharma, A. M. Smith, J. Chang, B. van Kessel, P. M. Nuttall and D. Crowther

467 **Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15**
T. Kukita, N. Arima, K. Matsushita, K. Arimura, H. Ohtsubo, Y. Sakaki, H. Fujiwara, A. Ozaki, T. Matsumoto and C. Tei

475 **Pamidronate causes apoptosis of plasma cells *in vivo* in patients with multiple myeloma**
S. Gordon, M. H. Helfrich, H. I. A. Sati, M. Greaves, S. H. Ralston, D. J. Culligan, R. L. Soutar and M. J. Rogers

Short reports

484 **Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome**
F. Cobo, L. Rosiñol, A. Martínez, F. Martín, J. Esteve, M. Gómez, E. Nadal, F. Bosch, F. J. Setoain, E. Campo and E. Montserrat

488 **Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph^+ adult acute lymphoblastic leukaemia**
G. Specchia, F. Albano, L. Anelli, C. T. Storlazzi, G. Cimino, A. Liso, A. Zagaria, V. Liso and M. Rocchi

492 **CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells**
H. Husson, A. S. Freedman, A. A. Cardoso, J. Schultze, O. Munoz, G. Strola, J. Kutok, E. G. Carideo, R. De Beaumont, F. Caligaris-Cappio and P. Ghia

496 **Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma**
R. Desikan, Y. Veksler, S. Raza, B. Stokes, T. Sabir, Z. Li and S. Jagannath

HAEMOPOIESIS AND LEUCOCYTES

500 **Influence of cell cycling and cell division on transendothelial migration of $CD34^+$ cells**
K. L. Yong, A. Fahey, A. Pizzey and D. C. Linch

510 **Developmental changes in the expression of transcription factors GATA-1, -2 and -3 during the onset of human medullary haematopoiesis**
C. Dame, M. C. Sola, J. Fandrey, L. M. Rimsza, P. Freitag, G. Knöpfle, R. D. Christensen and J. Bungert

516 **AC133$^+$ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis**
N. Forraz, R. Pettengell, P.-A. Deglesne and C. P. McGuckin

525 **Reconstitution of human haematopoiesis in non-obese diabetic/severe combined immunodeficient mice by clonal cells expanded from single CD34$^+$CD38$^-$ cells expressing Flk2/Flt3**
Y. Ebihara, M. Wada, T. Ueda, M.-j. Xu, A. Manabe, R. Tanaka, M. Ito, H. Mugishima, S. Asano, T. Nakahata and K. Tsuji

Short report 535 **Dominant expression of interleukin 10 but not interferon γ in CD4$^-$CD8$^-$ αβT cells of autoimmune lymphoproliferative syndrome**
S. Ohga, A. Nomura, Y. Takahata, K. Ihara, H. Takada, H. Wakiguchi, Y. Kudo and T. Hara

RED CELLS AND IRON

539 **Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (*SLC11A3*)**
M. Cazzola, L. Cremonesi, M. Papaioannou, N. Soriani, A. Kioumi, A. Charalambidou, R. Paroni, K. Romtsou, S. Levi, M. Ferrari, P. Arosio and J. Christakis

547 **Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients**
L. Sahlstedt, L. von Bonsdorff, F. Ebeling, T. Ruutu and J. Parkkinen

554 **Rapid detection of the major Mediterranean β-thalassaemia mutations by real-time polymerase chain reaction using fluorophore-labelled hybridization probes**
I. Moreno, P. Bolufer, M. L. Perez, E. Barragán and M. A. Sanz

558 **Exploring polycythaemia vera with fluorescence *in situ* hybridization: additional cryptic 9p is the most frequent abnormality detected**
V. Najfeld, L. Montella, A. Scalise and S. Fruchtman

567 **Chronic leg ulceration in homozygous sickle cell disease: the role of venous incompetence**
A. Clare, M. FitzHenley, J. Harris, I. Hambleton and G. R. Serjeant

CORRESPONDENCE

572 **Piebaldism in Diamond–Blackfan anaemia: a new phenotype?**
L. D. A. Costa, J. Fixler, O. Berets, T. Leblanc, T.-N. Willig, N. Mohandas and G. Tchernia

573 **Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen**
B. Nobili, G. Rossi, P. De Stefano, M. Zecca, G. Giorgiani, S. Perrotta, A. Canazzio and F. Locatelli

575 **Hyperbaric oxygen for cyclophosphamide-induced cystitis**
M. J. Hughes, F. M. Davis, S. D. Mark and R. L. Spearing

576 **Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions**
S. G. Jones, G. Dolan, K. Lengyel and B. Myers

578 **Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (Rituximab)**
S. Kain, T.-S. Copeland and M. F. Leahy

579 **Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?**
P. Schneider, M. Vasse, A. Al Bayati, B. Lenormand and J.-P. Vannier

581 **BOOK REVIEW**

Volume 119, Issue 3, December-I 2002

IMAGES IN HAEMATOLOGY

583 **Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia**
O. Maywald, G. Metzgeroth, C. Schoch, W. D. Ludwig, W. Neff, R. Hehlmann and J. Hastka

584 **Papillary endothelial hyperplasia in a bone marrow transplant recipient with extensive chronic graft-versus-host disease**
T. Yoshihara, T. Chiyonobu, A. Tatebe, A. Morimoto and S. Imashuku

REVIEWS

585 **X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective**
H. B. Gaspar, R. Sharifi, K. C. Gilmour and A. J. Thrasher

596 **Prevention and treatment of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants**
E. Meijer, A. W. Dekker, A. J. L. Weersink, M. Rozenberg-Arska and L. F. Verdonck

HAEMATOLOGICAL MALIGNANCY

608 **Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells**
V. Lecureur, A. Le Thiec, A. Le Meur, L. Amiot, B. Drenou, M. Bernard, T. Lamy, R. Fauchet and O. Fardel

616 **Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome**
K. Kojima, K. Kaneda, M. Yasukawa, K. Tanaka, T. Inoue, T. Yamashita, H. Dansako, S. T. Sakugawa, T. Kozuka, M. Hara and M. Tanimoto

622 **Molecular histogenesis of plasmablastic lymphoma of the oral cavity**
G. Gaidano, M. Cerri, D. Capello, E. Berra, C. Deambrogi, D. Rossi, L. M. Larocca, E. Campo, A. Gloghini, U. Tirelli and A. Carbone

629 **Intraclonal diversity in a Sezary syndrome with a differential response to 2-deoxycoformycin of the two lymphoma cell populations**
E. Granjo, M. Lima, J. M. Lopes, N. Cunha, M. A. Teixeira, F. Santos, J. Candeias, C. Resende, A. H. Santos, A. Balanzategui, A. Orfão and E. Matutes

634 **Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity**
R. Sonnen, W.-P. Schmidt, R. Kuse and N. Schmitz

640 **An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein–Barr virus-positive Hodgkin's lymphoma-derived cell line L591**
M. Vockerodt, G. Belge, D. Kube, J. Irsch, R. Siebert, H. Tesch, V. Diehl, J. Wolf, J. Bullerdiek and A. Staratschek-Jox

647 **ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies**
A. Atra, E. Higgs, M. Capra, A. Elsworth, J. Imeson, M. Radford and M. Hewitt on behalf of the UKCCSG/Hodgkin's Disease Group

652 **rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence *in situ* hybridization on May–Grunwald–Giemsa-stained bone marrow samples**
G. M. Rigolin, M. D. Porta, R. Bigoni, F. Cavazzini, M. Ciccone, A. Bardi, A. Cuneo and G. Castoldi

660 **Anti-myeloma activity of natural killer lymphocytes**
C. Frohn, M. Höppner, P. Schlenke, H. Kirchner, P. Koritke and J. Luhm

665 **Bone marrow angiogenesis in multiple myeloma: effect of therapy**
S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp and S. V. Rajkumar

672 **Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy**
C. Seidel, S. Lenhoff, S. Brabrand, G. Anderson, T. Standal, J. Lanng-Nielsen, I. Turesson, M. Børset and A. Waage for the Nordic Myeloma Study Group

677 **Soluble L-selectin (sCD62L) in relapsed childhood acute lymphoblastic leukaemia**
R. Herold, D. Stibenz, R. Hartmann, G. Henze and C. Bührer

685 **Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia**
P. Gameiro, I. Moreira, S. Yetgin, M. Papaioannou, M. N. Potter, H. G. Prentice, A. V. Hoffbrand and L. Foroni

697 **Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy**
K. Phekoo, H. Møller, M. Richards and S. Schey

Short reports

706 ***Helicobacter pylori* infection and monoclonal gammopathy of undetermined significance**
S. V. Rajkumar, R. A. Kyle, M. F. Plevak, J. A. Murray and T. M. Therneau

709 **Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis**
J. C. Wang, A. Novetsky, C. Chen and A. D. Novetsky

713 **High occurence of DRB1 11 in chronic lymphocytic leukaemia families**
I. Theodorou, L. Abel, F. Mauro, B. Duprey, C. Magnac, B. Payelle-Brogard, F. Davi and G. Dighiero

716 **Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8**
N. Fujii, K. Ikeda, N. Takahashi, K. Kojima, Y. Kobayashi, A. Ashiba, K. Takenaka, S. Fukuda, K. Shinagawa, F. Ishimaru, K. Niiya, I. Miura, M. Tanimoto and M. Harada

TRANSPLANTATION

720 **The prospective evaluation of a nested polymerase chain reaction assay for the early detection of *Aspergillus* infection in patients with leukaemia or undergoing allograft treatment**
R. B. Ferns, H. Fletcher, S. Bradley, S. Mackinnon, C. Hunt and R. S. Tedder

726 **Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study**
D. Farge, J. P. Marolleau, S. Zohar, Z. Marjanovic, J. Cabane, N. Mounier, E. Hachulla, P. Philippe, J. Sibilia, C. Rabian, S. Chevret and E. Gluckman for the Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group

740 **Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation**
J. Maciej Zaucha, M. Mielcarek, A. Takatu, M.-T. Little, T. Gooley, J. Baker, D. G. Maloney, B. M. Sandmaier, M. Maris, T. Chauncey, R. Storb and B. Torok-Storb

751 **An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation**
M. Remberger, U. Persson, D. Hauzenberger and O. Ringdén

760 **Intra-arterial catheter directed therapy for severe graft-versus-host disease**
M. Y. Shapira, A. I. Bloom, R. Or, T. Sasson, A. Nagler, I. B. Resnick, M. Aker, I. Zilberman, S. Slavin and A. Verstanding

Short reports

765 **A novel *DKC1* mutation, severe combined immunodeficiency ($T^+B^-NK^-$ SCID) and bone marrow transplantation in an infant with Hoyeraal–Hreidarsson syndrome**
F. Cossu, T. J. Vulliamy, A. Marrone, M. Badiali, A. Cao and I. Dokal

769 **Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia**
J. Hessling, N. Kröger, M. Werner, T. Zabelina, A. Hansen, U. Kordes, F. A. Ayuk, H. Renges, J. Panse, R. Erttmann and A. R. Zander

773 **Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units**
M. de Lima, L. S. St. John, E. D. Wieder, M. S. Lee, J. McMannis, S. Karandish, S. Giralt, M. Beran, D. Couriel, M. Korbling, S. Bibawi, R. Champlin and K. V. Komanduri

777 **Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma**
W. Y. Au, E. C. Chan, L. L. P. Siu, T. C. M. Lau, A. K. W. Lie, S. K. Ma and Y. L. Kwong

PLATELETS, HAEMOSTASIS AND THROMBOSIS

781 **Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome**
R. Takeuchi, T. Atsumi, M. Ieko, Y. Amasaki, K. Ichikawa and T. Koike

Short report

789 **The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency**
C. McMahon, J. Smith, C. Goonan, M. Byrne and O. P. Smith

HAEMOPOIESIS AND LEUCOCYTES

792 **Long-term *ex vivo* expansion of human fetal liver primitive haematopoietic progenitor cells in stroma-free cultures**
R. Peters, S. Leyvraz, E. Faes-van't Hull, P. Jaunin, S. Gerber and P. Rollini

803 **Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia**
W. Zeng, J. P. Maciejewski, G. Chen, A. M. Risitano, M. Kirby, S. Kajigaya and N. S. Young

810 **Telomere maintenance in human B lymphocytes**
U. M. Martens, V. Brass, L. Sedlacek, M. Pantic, C. Exner, Y. Guo, M. Engelhardt, P. M. Lansdorp, C. F. Waller and W. Lange

819 **BDCM: a novel B-cell line with genetic and functional similarity to dendritic cells**
S. Kharbanda, R. D. Salter, X. Dong, R. J. Tuma-Warrino and R. A. Steinman

Short reports

826 **The upregulation of CC chemokine receptor 7 and the increased migration of maturing dendritic cells to macrophage infammatory protein 3β and secondary lymphoid chemokine is mediated by the p38 stress-activated protein kinase pathway**
K. M. Ardeshna, A. R. Pizzey, S. J. Walker, S. Devereux and A. Khwaja

830 **Bone marrow failure in Shwachman–Diamond syndrome does not select for clonal haematopoiesis of the paroxysmal nocturnal haemoglobinuria phenotype**
P. Keller, M. R. Debaun, R. J. Rothbaum and M. Bessler

RED CELLS AND IRON

833 **Exposure of erythrocytes to methylene blue shows the active role of catalase in removing hydrogen peroxide**
G. F. Gaetani, D. Rapezzi, R. Mangerini, O. Racchi, M. Rolfo and A. M. Ferraris

839 **Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome**
S. Ladhani, B. Lowe, A. O. Cole, K. Kowuondo and C. R. J. C. Newton

848 **Genetic polymorphism of the major regulatory element HS-40 upstream of the human α-globin gene cluster**
C. L. Harteveld, M. Muglia, G. Passarino, M. F. Kielman and L. F. Bernini

Short reports

855 **Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea**
M. Nahavandi, F. Tavakkoli, M. Q. Wyche, E. Perlin, W. P. Winter and O. Castro

858 **A patient with paroxysmal nocturnal haemoglobinuria in whom granulocyte colony-stimulating factor administration resulted in improvement of recurrent enterocolitis and its associated haemolytic attacks**
A. Fujimi, T. Matsunaga, K. Kogawa, T. Ohnuma, N. Takahira, T. Abe, K. Kitaoka, T. Kogawa, I. Tanaka, K. Morii, T. Terui, S. Sakamaki, J. Kato, T. Kura, T. Maeda and Y. Niitsu

TRANSFUSION

863 **The expression of prion protein by endothelial cells: a source of the plasma form of prion protein?**
R. Starke, O. Drummond, I. MacGregor, J. Biggerstaff, R. Gale, R. Camilleri, I. Mackie, S. Machin and P. Harrison

CORRESPONDENCE

874 **Spontaneous remission of B-chronic lymphocytic leukaemia**
E. B. Gómez García, E. G. van Lochem, K. van Lom and H. Hooijkaas

875 **Anti-phospholipid/cofactor antibodies in three cases of persistent polyclonal B lymphocytosis**
B. Granel, J. Serratrice, P. Disdier, M. SanMarco, M. M. Hubert, M.-C. Alessi, H. Cannoni, L. Camoin, R. Bouabdallah, I. Juhan-Vague and P.-J. Weiller

877 **Clinicopathological correlation, p16-p15 methylation status and outcome predictors in anaplastic large cell lymphoma**
M. J. García, J. M. Castrillo, J. J. Granizo, A. Cazorla and C. Rivas

878 **The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia**
R. V. Thomas, H. Bessos, M. L. Turner, E. H. Horn and C. A. Ludlam

880 **Management dilemma of cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia**
R. A. G. Saad, L. Horn and P. S. Mankad

881 **EPCR 23 bp insertion in a patient with severe progressive arterial disease: a dominant loss of function mutant in conditions of increased APC request?**
G. Zecchina, S. Bosio, E. Brusa, G. Rege-Cambrin and C. Camaschella

882 **B_{12} deficiency: not an uncommon genetic-related disorder**
G. Delpre, P. Stark and Y. Niv

883 **Thalidomide in combination with cyclophosphamide and dexamethasone (Thacydex) is effective in soft-tissue plasmacytomas**
J. R. González-Porras, M. González, R. García-Sanz and J. F. San Miguel

885 **ANNOUNCEMENT**

886 **ERRATA**

Volume 119, Issue 4, December-II 2002

IMAGES IN HAEMATOLOGY

887 **Cardiac involvement in non-Hodgkin's lymphoma**
M. Magagnoli, A. Nozza, F. R. Lutman and A. Santoro

888 **Haemopoietic and neuroglial progenitors are promoted during cord blood *ex vivo* expansion**
N. Forraz, R. Pettengell and C. P. McGuckin

HISTORICAL REVIEWS

889 **Red cell agglutination: the first description by Creite (1869) and further observations made by Landois (1875) and Landsteiner (1901)**
N. C. Hughes-Jones and B. Gardner

894 **Historical aspects and present knowledge of idiopathic thrombocytopenic purpura**
P. Imbach, T. Kühne and E. Signer

901 **Fanconi and Glanzmann: the men and their works**
R. F. Stevens and S. Meyer

HAEMATOLOGICAL MALIGNANCY

905 **Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma**
Y. Zhu, J. Hollmén, R. Räty, Y. Aalto, B. Nagy, E. Elonen, J. Kere, H. Mannila, K. Franssila and S. Knuutila

916 **Intrasinusoidal bone marrow infiltration: a common growth pattern for different lymphoma subtypes**
V. Costes, E. Duchayne, J. Taib, C. Delfour, T. Rousset, P. Baldet, G. Delsol and P. Brousset

923 **Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab**
J. Golay, R. Gramigna, V. Facchinetti, D. Capello, G. Gaidano and M. Introna

930 **A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence *in situ* hybridization detects the *MLL* translocation without cytogenetic evidence both initially and during follow-up**
H. J. Kim, H. I. Cho, E. C. Kim, E. K. Ko, C. J. See, S. Y. Park and D. S. Lee

940 **Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia**
O. Sasaki, K. Meguro, Y. Tohmiya, T. Funato, S. Shibahara and T. Sasaki

949 **The naive T-lymphocyte compartment is well preserved in patients with chronic myelogenous leukaemia in chronic phase**
A. Isoda, A. Yokohama, T. Matsushima, N. Tsukamoto, Y. Nojima and M. Karasawa

956 **Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival**
K. Higginbottom, M. Cummings, A. C. Newland and P. D. Allen

965 **Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia**
R. Crazzolara, K. Jöhrer, R. W. Johnstone, R. Greil, R. Kofler, B. Meister and D. Bernhard from the Tyrolean Cancer Research Institute (TCRI) at the University of Innsbruck

970 **Novel flow-cytometric analysis based on BCD5$^+$ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia**
K. Maloum, L. Sutton, S. Baudet, C. Laurent, P. Bonnemye, C. Magnac and H. Merle-Béral

976 **Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia**
F. Bosch, A. Ferrer, A. López-Guillermo, E. Giné, B. Bellosillo, N. Villamor, D. Colomer, F. Cobo, M. Perales, J. Esteve, A. Altés, J. Besalduch, J. M. Ribera and E. Montserrat for the GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears)

Short reports

985 **Genetic polymorphisms in the tumour necrosis factor locus in childhood acute lymphoblastic leukaemia**
S. Takeuchi, N. Takeuchi, K. Tsukasaki, C. R. Bartram, M. Zimmermann, M. Schrappe, H. Taguchi and H. P. Koeffler

988 **Infrequent hypermethylation of *CEBPA* promotor in acute myeloid leukaemia**
C. S. Chim, A. S. Y. Wong and Y. L. Kwong

PLATELETS, HAEMOSTASIS AND THROMBOSIS

991 **Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb–IIIa antibodies**
I. Martin, F. Kriaa, V. Proulle, B. Guillet, C. Kaplan, R. d'Oiron, M. Debré, E. Fressinaud, Y. Laurian, G. Tchernia, B. Charpentier, T. Lambert and M. Dreyfus

998 **Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an *ex vivo* perfusion chamber model**
P. Hainaud, J.-P. Brouland, P. André, G. Simoneau, C. Bal dit Sollier, L. Drouet, J. Caen and S. Bellucci

1005 **Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study**
S. S. Runchey, A. R. Folsom, M. Y. Tsai, M. Cushman and P. D. McGovern

1011 **Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia**
P. O. Iversen, P. D. E. Groot, N. Hjeltnes, T. O. Andersen, M. C. Mowinckel and P. M. Sandset

1017 **Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women**
M. S. Post, J. Rosing, M. J. van der Mooren, S. Zweegman, W. M. van Baal, P. Kenemans and C. D. A. Stehouwer for the Project 'Ageing Women' and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU)

1024 **Activation of integrin αIIbβ3 expressed in Chinese hamster ovary cells is required for interaction with solid-phase von Willebrand factor**
M. Mekrache, P. Legendre, N. Kieffer and D. Baruch

1033 **Mechanisms involved in the antiplatelet activity of magnesium in human platelets**
J.-R. Sheu, G. Hsiao, M.-Y. Shen, T.-H. Fong, Y.-W. Chen, C.-H. Lin and D.-S. Chou

1042 **Activation and inactivation of human factor X by proteases derived from *Ficus carica***
G. Richter, H. P. Schwarz, F. Dorner and P. L. Turecek

1052 **Two double heterozygous mutations in the F7 gene show different manifestations**
K. Nagaizumi, H. Inaba, T. Suzuki, Y. Hatta, T. Hagiwara, K. Amano, M. Arai and K. Fukutake

Short report 1059 **Clonal T cell-mediated cyclic thrombocytopenia**
W. Füreder, G. Mitterbauer, R. Thalhammer, K. Geissler, S. Panzer, M. Krebs, I. Simonitsch-Klupp, W. R. Sperr, K. Lechner and P. A. Kyrle

HAEMOPOIESIS AND LEUCOCYTES

1062 **Does isochromosome 7q mandate bone marrow transplant in children with Shwachman–Diamond syndrome?**
J. Cunningham, M. Sales, A. Pearce, J. Howard, R. Stallings, N. Telford, R. Wilkie, B. Huntly, A. Thomas, A. O'Marcaigh, A. Will and N. Pratt

1070 **Expression and function of pituitary tumour transforming gene for T-lymphocyte activation**
R. Stoika, R. Yu and S. Melmed

1075 **Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia**
E. Gluckman, R. Rokicka-Milewska, I. Hann, E. Nikiforakis, F. Tavakoli, S. Cohen-Scali and A. Bacigalupo for the European Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anemia

1083 **Human bone marrow angiogenesis: *in vitro* modulation by substance P and neurokinin A**
L. Pelletier, R. Angonin, J. Regnard, D. Fellmann and P. Charbord

1090 **Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients**
P. Casassus, N. Caillat-Vigneron, A. Martin, J. Simon, V. Gallais, P. Beaudry, V. Eclache, L. Laroche, P. Lortholary, M. Raphaël, L. Guillevin and O. Lortholary

RED CELLS

1098 **Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways**
M. Wang, D. C. Tang, W. Liu, K. Chin, J. G. Zhu, E. Fibach and G. P. Rodgers

1106 **A 3′UTR mutation affects β-globin expression without altering the stability of its fully processed mRNA**
O. Bilenoglu, A. N. Basak and J. E. Russell

TRANSPLANTATION

1115 **Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide–total body irradiation versus busulphan–cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission**
M. R. Litzow, W. S. Pérez, J. P. Klein, B. J. Bolwell, B. Camitta, E. A. Copelan, R. P. Gale, S. A. Giralt, A. Keating, H. M. Lazarus, D. I. Marks, P. L. McCarthy, C. B. Miller, G. Milone, H. G. Prentice, J. A. Russell, K. R. Schultz, M. E. Trigg, D. J. Weisdorf and M. M. Horowitz

1125 **Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality**
S. Chakrabarti, I. Avivi, S. Mackinnon, K. Ward, P. D. Kottaridis, H. Osman, H. Waldmann, G. Hale, C. D. Fegan, K. Yong, A. H. Goldstone, D. C. Linch and D. W. Milligan

Short report 1133 **The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation**
A. Nordlander, M. Uzunel, J. Mattsson and M. Remberger

CORRESPONDENCE

1137 **Oral anticoagulation and dental extractions**
A. J. Gibbons and A. W. Sugar

1137 **Low-grade rectal malt lymphoma occurring in a patient with chronic lymphocytic leukaemia**
J. Rey, D. Coso, O. Ramuz, L. Xerri, D. Sainty, M. Giovannini and R. Bouabdallah

1139 **How frequent is mutation in the mitochondrial cytochrome c oxidase gene in patients with myelodysplastic syndromes?**
N. Gattermann, M. Wulfert and G. Hofhaus

1139 **Reply to Gattermann *et al***
P. Reddy and A. Raza

1141 **Recurrent thromboembolism in a familial pseudohyperkalaemia patient with an intact spleen**
T. Latham, G. W. Stewart and E. H. Horn

1142 **BOOK REVIEW**

1143 **AUTHOR AND KEYWORD INDEXES FOR VOLUME 119**